Brief: Zai Lab Announces Inclusion Of QINLOCK and NUZYRA In China’s National Reimbursement Drug List
Jan 18 (Reuters) - Zai Lab Ltd 9688.HK :
* ZAI LAB ANNOUNCES INCLUSION OF QINLOCK® (RIPRETINIB) AND
NUZYRA®
(OMADACYCLINE) IN CHINA’S NATIONAL REIMBURSEMENT DRUG LIST
Source text for Eikon: ID:nGNX76hgtW
Further company coverage: 9688.HK
Recent news on Zai Lab
See all newsBrief: Zai Lab Says ZL-1503 Was Well Tolerated With No Serious Adverse Events
Brief: Zai Lab Agrees To Issue To Investors Aggregate Of 11.3 Million ADSs
Zai Lab's Hong Kong shares hit three-month high on quarterly revenue beat
Brief: U.S. FDA Grants Orphan Drug Designation To Zai Lab’S Dll3-Targeting Adc Zocilurtatug Pelitecan (Zoci) For The Treatment Of Neuroendocrine Carcinomas (Necs)
Brief: Goldman Sachs Group's Long Position In Zai Lab Decreases On May 14, HKEX Filing Shows